Did you know that non-alcoholic steatohepatitis, or NASH is a type of nonalcoholic fatty liver disease? If you have NASH you have inflammation, excessive fat and cell damage in your liver. Dr. John Goff from the Rocky Mountain Gastroenterology Centers in Denver will be discussing the scope of the problem, the effects on the liver, who is at most risk and additional injuries that can be caused and what you can do to be healthier.
Video Rating: / 5
Non-alcoholic steatohepatitis (NASH) is a growing public health issue, affecting an estimated three to five percent of the global adult population. It typically progresses slowly with few – if any – obvious or visible symptoms, making it a largely unrecognized and underdiagnosed disease. Learn more about how NASH develops and progresses in the body, as well as our approach to uncovering potential treatments.
Understanding NASH (Non-Alcoholic Steatohepatitis)
Video Rating: / 5
Non-alcoholic steatohepatitis (NASH) is the most serious form of non-alcoholic fatty liver disease (NAFLD). NASH is defined by the presence of the 3 following lesions in hepatocytes (specialized liver cells): steatosis, inflammation and ballooning. Inflammation and hepatocellular ballooning are commonly considered as the drivers of disease progression.
Individuals with associated metabolic disorders such as insulin resistance, type 2 diabetes and obesity are particularly at higher risk to progress to NASH. NASH can evolve to cirrhosis or hepatocellular carcinoma, but it is much more than just a liver disease. It also increases the risk of life-threatening cardiovascular events.
The NASH Education Program™ aims at developing and conducting relevant disease awareness actions in the NASH space.
More information on: www.the-nash-education-program.com
↓↓↓ MORE VIDEOS ↓↓↓
NASH WebTV: https://youtu.be/ND3AVP3Au0w
NASH diagnosis: https://youtu.be/k1U7_l9kORY
NAFLD/NASH: Anticipating an impending storm: https://youtu.be/8gmLOhP3ztQ
Works from The NASH Education Program are the property of GENFIT and are protected by IP rights. They are reproduced with the authorization of GENFIT
